Servier Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SERVIER, and what generic alternatives to SERVIER drugs are available?
SERVIER has two approved drugs.
There are fourteen US patents protecting SERVIER drugs.
There are two hundred and thirty-three patent family members on SERVIER drugs in forty-four countries and twelve supplementary protection certificates in eleven countries.
Summary for Servier
| International Patents: | 233 |
| US Patents: | 14 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Servier
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Servier | VORANIGO | vorasidenib | TABLET;ORAL | 218784-002 | Aug 6, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| Servier | VORANIGO | vorasidenib | TABLET;ORAL | 218784-001 | Aug 6, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Servier | TIBSOVO | ivosidenib | TABLET;ORAL | 211192-001 | Jul 20, 2018 | RX | Yes | Yes | 9,850,277 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Servier | VORANIGO | vorasidenib | TABLET;ORAL | 218784-002 | Aug 6, 2024 | RX | Yes | Yes | 10,172,864 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Servier | VORANIGO | vorasidenib | TABLET;ORAL | 218784-001 | Aug 6, 2024 | RX | Yes | No | 9,579,324 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Servier Drugs
Supplementary Protection Certificates for Servier Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2804851 | C202330033 | Spain | ⤷ Sign Up | PRODUCT NAME: IVOSIDENIB O UNA SAL, TAUTOMERO, ISOTOPOLOGO O HIDRATO FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/23/1728; DATE OF AUTHORISATION: 20230504; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/23/1728; DATE OF FIRST AUTHORISATION IN EEA: 20230504 |
| 2804851 | C20230022 00409 | Estonia | ⤷ Sign Up | PRODUCT NAME: IVOSIDENIIB;REG NO/DATE: EU/1/23/1728 08.05.2023 |
| 2804851 | 301243 | Netherlands | ⤷ Sign Up | PRODUCT NAME: IVOSIDENIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT, TAUTOMEER, ISOTOPOLOOG OF HYDRAAT DAARVAN; REGISTRATION NO/DATE: EU/1/23/1728 20230508 |
| 2804851 | 23C1031 | France | ⤷ Sign Up | PRODUCT NAME: IVOSIDENIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, UN TAUTOMERE, UN ISOTOPOLOGUE OU UN HYDRATE D'IVOSIDENIB; REGISTRATION NO/DATE: EU/1/23/1728 20230508 |
| 2804851 | 122023000051 | Germany | ⤷ Sign Up | PRODUCT NAME: LVOSIDENIB ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ, TAUTOMER, ISOTOPOLOG ODER HYDRAT DAVON; REGISTRATION NO/DATE: EU/1/23/1728 20230504 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
